LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

Search

iRhythm Technologies Inc

Open

SectorGezondheidszorg

135.87 -4.91

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

135.42

Max

140.82

Belangrijke statistieken

By Trading Economics

Inkomsten

9M

-5.2M

Verkoop

6.2M

193M

Winstmarge

-2.702

Werknemers

2,000

EBITDA

7.7M

2.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+50.35% upside

Dividenden

By Dow Jones

Volgende Winsten

30 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.2B

4.6B

Vorige openingsprijs

140.78

Vorige sluitingsprijs

135.87

Nieuwssentiment

By Acuity

50%

50%

149 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

iRhythm Technologies Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb 2026, 22:36 UTC

Winsten

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb 2026, 22:32 UTC

Winsten

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb 2026, 23:58 UTC

Marktinformatie
Winsten

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb 2026, 23:58 UTC

Marktinformatie
Winsten

Global Energy Roundup: Market Talk

23 feb 2026, 23:47 UTC

Marktinformatie

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb 2026, 23:43 UTC

Marktinformatie

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb 2026, 23:41 UTC

Acquisities, Fusies, Overnames

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb 2026, 23:40 UTC

Marktinformatie

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb 2026, 23:39 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb 2026, 23:31 UTC

Winsten

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb 2026, 23:31 UTC

Winsten

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb 2026, 23:27 UTC

Winsten

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb 2026, 23:24 UTC

Marktinformatie

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb 2026, 22:31 UTC

Winsten

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 22:24 UTC

Winsten

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb 2026, 22:21 UTC

Winsten

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb 2026, 22:21 UTC

Winsten

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb 2026, 22:20 UTC

Winsten

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Vergelijking

Prijswijziging

iRhythm Technologies Inc Prognose

Koersdoel

By TipRanks

50.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 212.33 USD  50.35%

Hoogste 254 USD

Laagste 184 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor iRhythm Technologies Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Technische score

By Trading Central

104.78 / 137.91Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

149 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
help-icon Live chat